-- 加拿大皇家銀行資本市場（RBC Capital Markets）週一發布的一份報告指出，輝瑞（PFE）的tafamidis藥物的庭審將於下週開始，根據對三種核心結果情景的建模分析，該案顯示出不對稱的上漲空間，在悲觀情景和樂觀情景之間，淨現值差異高達50億美元。 這家投資公司表示，該訴訟的關鍵在於將於2035年到期的“441”多晶型物專利，該專利“在科學上最薄弱”，因為“695”化合物和“696”用途專利預計將繼續有效。 RBC估計，輝瑞勝訴的機率為19%，屆時該公司將證明存在侵權行為，並獲得專利保護至2035年，淨現值將超過60億美元。 報告也指出，雙方打成平手的機率為60%，仿製藥將於2032年左右上市，淨現值將超過30億美元。 此外，輝瑞表示，其多晶型專利敗訴的機率為21%，這意味著仿製藥將於2028年上市，而這項預期目前已反映在該公司股價中。 加拿大皇家銀行維持對該股的「弱於大盤」評級，目標價為25美元。
Price: $27.77, Change: $+0.21, Percent Change: +0.74%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.